Wave Life Sciences (WVE) Announces Earnings Results, Misses Estimates By $0.02 EPS

Share on StockTwits

Wave Life Sciences (NASDAQ:WVE) posted its quarterly earnings results on Friday. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.02), MarketWatch Earnings reports. The business had revenue of $4.49 million for the quarter, compared to analyst estimates of $5.36 million. Wave Life Sciences had a negative return on equity of 91.88% and a negative net margin of 1,473.26%.

NASDAQ:WVE traded down $2.07 on Friday, hitting $43.16. The stock had a trading volume of 56,859 shares, compared to its average volume of 77,911. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.11 and a quick ratio of 6.11. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -11.21 and a beta of 1.10. Wave Life Sciences has a 1-year low of $21.85 and a 1-year high of $56.00.

Several equities analysts have weighed in on the stock. BidaskClub lowered shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, September 28th. Stifel Nicolaus assumed coverage on shares of Wave Life Sciences in a report on Monday, August 6th. They issued a “buy” rating and a $56.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $49.00 target price on shares of Wave Life Sciences in a report on Monday, July 23rd. Finally, Mizuho set a $65.00 target price on shares of Wave Life Sciences and gave the company a “buy” rating in a report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $58.40.

In other Wave Life Sciences news, insider Chris Francis sold 11,575 shares of the business’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $56.00, for a total value of $648,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Keith Regnante sold 29,500 shares of the business’s stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $55.00, for a total transaction of $1,622,500.00. The disclosure for this sale can be found here. Insiders sold a total of 44,075 shares of company stock worth $2,435,700 over the last quarter. 44.20% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://weekherald.com/2018/11/10/wave-life-sciences-wve-announces-earnings-results-misses-estimates-by-0-02-eps.html.

About Wave Life Sciences

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Further Reading: How is a Moving Average Calculated?

Earnings History for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply